Qlife Holding announces the outcome of the exercise of warrants series TO 3
Qlife Holding AB (“Qlife” or the “Company”) today announces the outcome of the exercise period for warrants series TO 3, which were issued in connection with the Company’s rights issue of units in April 2023 (the “Rights Issue”). The subscription rate was approximately 0.02 per cent and Qlife thereby receives approximately SEK 14 thousand before issue costs.
In total, Qlife issued 622,348,940 units in the Rights Issue, each consisting of one (1) share and one (1) warrant series TO 3. One (1) warrant entitled the right to subscribe for one (1) new share in the Company at a fixed exercise price of SEK 0.11 per share, which exceeded the Company’s share price during the exercise period of the warrants that ran from 11 – 29 September 2023.
The outcome shows that 126,250 warrants were utilized for subscription of 126,250 shares, meaning a subscription rate of approximately 0.02 per cent. Exercised warrants have been replaced with interim shares pending registration with the Swedish Companies Registration Office. The interim shares are expected to be converted into shares during week 40, 2023.
Through the exercise of the warrants the Company receives approximately SEK 14 thousand before issue costs. The total number of shares in Qlife increases by 126,250, from 645,435,499 to 645,561,749. The share capital in Qlife increases by SEK 10,100.00, from SEK 51,634,839.92 to SEK 51,644,939.92.
The information was submitted for publication, through the agency of the contact person set out below, on 2023-10-03 12:12 CET.
For more information please contact:
Thomas Warthoe, CEO
tw@egoo.health
+45 21 63 35 34
Qlife is a medical device company born to challenge the status quo in healthcare. We work to shift the perspective and turn today's view on healthcare into tomorrow's focus on health- empowerment. We are on a quest to empower people with more accessible ways to understand their health - so that they can move beyond reactive care towards proactive wellbeing. It's how we contribute to improving quality of life for every individual and for the greater society.
Shares for Qlife are being traded on Nasdaq First North Growth Market in Stockholm with G&W Fondkommission as certified advisor.
Read more on Egoo.health, Qlifeholding.com or follow us on LinkedIn.
Important information
The information in this press release does not contain or constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants or other securities in Qlife. Invitation to the persons concerned to subscribe for units consisting of shares and warrants in Qlife has only taken place through the prospectus that Qlife published on 6 April 2023, and the supplementary prospectus that was published on 19 April 2023.